Skip to main content

Table 1 Overall population characteristics (per patients) and comparison of hospital stays between pre- and post-intervention periods

From: Antimicrobial stewardship in high-risk febrile neutropenia patients

Patients characteristics Pre-intervention period
Jan–Oct 2018
N = 164 patients
Post-intervention period
Jan–Oct 2019
N = 148 patients
p value
Age (year); Median [IQR] 60.4 [49.4–71.9] 65.2 [54.3–72.8] 0.049
Sex (female); N (%) 78 (47.6) 65 (43.9) 0.60
Charlson comorbidity index; Median [IQR] 2 [2–4] 2 [2–6] 0.54
Number of stays; Median [IQR] 1 [1–2] 1 [1–2] 0.49
Hematological disease; N (%)    0.44
 Myeloma 37 (22.6) 45 (30.4)  
 Acute myeloid leukemia 31 (18.9) 32 (21.6)  
 Aggressive lymphoma 28 (17.1) 26 (17.6)  
 Indolent lymphoma 20 (12.2) 9 (6.1)  
 ALL/LBL 18 (11) 11 (7.4)  
 Myelodysplastic syndrome 7 (4.3) 9 (6.1)  
 Hodgkin lymphoma 6 (3.7) 4 (2.7)  
 Aplastic anemia 5 (3) 5 (3.4)  
 Other 12 (7.3) 7 (4.7)  
Hospital stays characteristics Pre-intervention period
Number of hospital stay = 273
Post-intervention period
Number of hospital stay = 217
p-value
Total number of patient-days 3180 3129
Cause of hospitalization; N (%)    0.28
 Intensive or induction chemotherapy 57 (20.9) 38 (17.5)  
 Leukemia consolidation chemotherapy 32 (11.7) 27 (12.4)  
 Chemotherapy (other) 67 (24.5) 49 (22.6)  
 Autologous BMT 51 (18.7) 48 (22.1)  
 Transfusion 9 (3.3) 9 (4.1)  
 Palliative care 4 (1.5) 5 (2.4)  
 Aplasia 1 (0.4) 5 (2.4)  
 Antithymocyte globulin + ciclosporin 1 (0.4) 4 (1.8)  
 Other 51 (18.6) 32 (14.7)  
Number of stays with febrile episode; N (%) 118 (43.2) 116 (53.5) 0.031
  1. ALL: Acute lymphoblastic leukemia; LBL: Lymphoblastic lymphoma